Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4838084 | 0.93 | MAPT (0.43) | ADRB1ADRB2MAPT | |
| Trifluoroacetic Acid SCHEMBL4838285 | 0.92 | ADRB1 (0.42) | KDM4EMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL4834743 | 0.89 | TRPV3 (0.39) | TRPV3 | |
| Trifluoroacetic Acid SCHEMBL5260635 | 0.87 | — | — | |
| Trifluoroacetic Acid SCHEMBL4834992 | 0.84 | HDAC3 (0.36) | — | |
| SCHEMBL4834900 | 0.84 | MAPT (0.45) | ADRB1ADRB2MAPT | |
| Trifluoroacetic Acid SCHEMBL4844208 | 0.83 | CYP3A4 (0.46) | KDM4EALDH1A1ADRB1ADRB2 | |
| Trifluoroacetic Acid SCHEMBL4834809 | 0.83 | KMT2A (0.44) | KDM4EMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL5258414 | 0.82 | MEN1 (0.43) | MEN1KMT2AADRB1ADRB2 | |
| Trifluoroacetic Acid SCHEMBL4834060 | 0.82 | KDM4E (0.39) | KDM4EMEN1ALDH1A1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7410966-B2 | Use of and some novel imidazopyridines | ASTRAZENECA AB (SE) | 2008-08-12 | — | — | US | disclosed |
| EP-1539759-B1 | NOVEL IMIDAZOPYRIDINES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | EP | disclosed |
| US-20050261333-A1 | Use of and some novel imidazopyridines | ASTRAZENECA A B (SE) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261333-A1 | Use of and some novel imidazopyridines | ITK, CSNK1A1, RPS6KA1 | KDM4E 2903/4885MEN1 2592/4885ALDH1A1 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.